ADVAIR
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $196,300 | 1 | 0 |
| 2022 | $39.30 | 2 | 2 |
| 2019 | $4,620 | 22 | 21 |
| 2018 | $435,402 | 11,346 | 7,153 |
| 2017 | $457,259 | 20,512 | 10,766 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $645,842 | 160 | 59.1% |
| Food and Beverage | $440,814 | 31,709 | 40.3% |
| Consulting Fee | $6,215 | 13 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750.00 | 1 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $273,500 | 51 |
| 0000000000000000000000000000000000000000000000000000000000000000213289 | GlaxoSmithKline, LLC. | $196,300 | 0 |
| A 6-MONTH SAFETY AND BENEFIT STUDY OF INHALED FLUTICASONE PROPIONATE/ | GlaxoSmithKline, LLC. | $172,981 | 0 |
| SAS115359, A SAFETY AND EFFICACY STUDY OF INHALED FLUTICASONE PROPIONA | GlaxoSmithKline, LLC. | $2,413 | 0 |
Top Doctors Receiving Payments for ADVAIR — Page 567
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Denver, CO | $3.75 | 1 |
| , MD | Family Medicine | Philadelphia, PA | $3.72 | 1 |
| , M.D | Internal Medicine | New Haven, CT | $3.70 | 1 |
| , M.D | Internal Medicine | New Haven, CT | $3.70 | 1 |
| , DO | Family Medicine | Dyer, IN | $3.68 | 2 |
| , MD | Family Medicine | Fort Wayne, IN | $3.66 | 1 |
| , MD | Allergy & Immunology | Wichita, KS | $3.49 | 1 |
| , M.D | Internal Medicine | Las Vegas, NV | $3.46 | 1 |
| , M.D | Internal Medicine | Monaca, PA | $3.41 | 1 |
| , D.O | Internal Medicine | Beaver, PA | $3.41 | 1 |
| , MD | Internal Medicine | Waipahu, HI | $3.41 | 1 |
| , DO | Internal Medicine | Beaver, PA | $3.41 | 1 |
| , M.D | Family Medicine | Merrillville, IN | $3.36 | 2 |
| , M.D | Family Medicine | Merrillville, IN | $3.35 | 2 |
| , MD | Internal Medicine | Mobile, AL | $3.15 | 1 |
| , MD | Pulmonary Disease | Wichita, KS | $2.88 | 1 |
| , D.O | Internal Medicine | Banning, CA | $2.75 | 1 |
| , M.D | Allergy & Immunology | Sterling Heights, MI | $2.74 | 1 |
| , D.O | Family Medicine | Dallas, TX | $2.71 | 1 |
| , MD | Family Medicine | Scottsdale, AZ | $2.65 | 1 |
| , M.D | Internal Medicine | New York, NY | $2.58 | 1 |
| , M.D | Family Medicine | Pensacola, FL | $2.57 | 1 |
| , DO | Critical Care Medicine | Twin Falls, ID | $2.31 | 1 |
| , MD | Specialist | New Castle, PA | $2.17 | 1 |
| , D.O | Family Medicine | Belle Vernon, PA | $2.07 | 1 |
Manufacturing Companies
- GlaxoSmithKline, LLC. $820,120
- Lupin Inc. $273,500
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 14,195
- Transactions 31,883
About ADVAIR
ADVAIR is a drug associated with $1.1M in payments to 14,195 healthcare providers, recorded across 31,883 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2024. In 2024, $196,300 was paid across 1 transactions to 0 doctors.
The most common payment nature for ADVAIR is "Unspecified" ($645,842, 59.1% of total).
ADVAIR is associated with 4 research studies, including "A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS" ($273,500).